{"id":"capox-3-month","safety":{"commonSideEffects":[{"rate":"27%","effect":"Hand-foot syndrome"},{"rate":"21%","effect":"Diarrhea"},{"rate":"20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1835901","moleculeType":"Small molecule","molecularWeight":"298.34"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Capecitabine is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which then inhibits thymidylate synthase, leading to the disruption of DNA synthesis and cell death in rapidly dividing cancer cells.","oneSentence":"Capecitabine is a thymidylate synthase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:00.844Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Breast cancer"},{"name":"Stomach cancer"}]},"trialDetails":[{"nctId":"NCT07001748","phase":"PHASE2, PHASE3","title":"Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2025-08-19","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":148},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT07413146","phase":"NA","title":"Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Minimal Residual Disease, Immunoscore, Neoadjuvant Chemotherapy","enrollment":100},{"nctId":"NCT06107920","phase":"PHASE3","title":"Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-05-07","conditions":"Colon Cancer","enrollment":232},{"nctId":"NCT07340567","phase":"PHASE3","title":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-01","conditions":"Colorectal Cancer","enrollment":2450},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT07188025","phase":"PHASE3","title":"ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-10","conditions":"Rectal Cancer","enrollment":103},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT06834126","phase":"PHASE1","title":"Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-04-07","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":36},{"nctId":"NCT06434896","phase":"NA","title":"Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2020-03-05","conditions":"Circulating Tumor DNA, Recurrence, Colon Cancer Stage II","enrollment":1320},{"nctId":"NCT06899477","phase":"PHASE3","title":"Pre-Operative Treatment in REseCTable COlon CanceR","status":"NOT_YET_RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2025-04","conditions":"Colo-rectal Cancer, Colon Cancer, Colon Carcinoma","enrollment":714},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT06753721","phase":"PHASE1, PHASE2","title":"An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-12-31","conditions":"Advanced Colorectal Adenocarcinoma","enrollment":13},{"nctId":"NCT04488159","phase":"PHASE3","title":"Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer","status":"WITHDRAWN","sponsor":"Johannes Laengle, MD, PhD","startDate":"2024-12-01","conditions":"Colon Cancer Stage III","enrollment":""},{"nctId":"NCT06194981","phase":"","title":"Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-11","conditions":"Gastric Cancer","enrollment":260},{"nctId":"NCT03607656","phase":"PHASE2, PHASE3","title":"The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2018-06-08","conditions":"Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC","enrollment":270},{"nctId":"NCT03802591","phase":"PHASE3","title":"A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2019-03-28","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":479},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT00958737","phase":"PHASE3","title":"Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2009-05-12","conditions":"Colorectal Cancer","enrollment":2000},{"nctId":"NCT04259944","phase":"PHASE2","title":"Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial","status":"UNKNOWN","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2020-06-16","conditions":"Colon Cancer","enrollment":140},{"nctId":"NCT02974556","phase":"PHASE3","title":"Proactive Management of Endoperitoneal Spread in Colonic Cancer","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2024-03-01","conditions":"Colon Cancer, Intraperitoneal Rectal Cancer","enrollment":140},{"nctId":"NCT05673343","phase":"","title":"The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-01-04","conditions":"the Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatment","enrollment":100},{"nctId":"NCT03748680","phase":"PHASE2","title":"IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"Karen-Lise Garm Spindler","startDate":"2018-10-01","conditions":"Colorectal Cancer, Circulating Tumor DNA, Adjuvant Chemotherapy","enrollment":64},{"nctId":"NCT02231086","phase":"PHASE3","title":"Adjuvant HIPEC in High Risk Colon Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-03","conditions":"Colorectal Neoplasms, Peritoneal Neoplasms","enrollment":204},{"nctId":"NCT01092481","phase":"PHASE3","title":"Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-01-26","conditions":"Colon Cancer","enrollment":1580},{"nctId":"NCT03422601","phase":"","title":"Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2017-07-13","conditions":"Colorectal Cancer, Stage III Colon Cancer","enrollment":1122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CAPOX 3 month","genericName":"CAPOX 3 month","companyName":"NRG Oncology","companyId":"nrg-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a thymidylate synthase inhibitor. Used for Colorectal cancer, Breast cancer, Stomach cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}